NEC’s Artificial Intelligence (AI) Supports Doctors to Determine If Colorectal Lesions Are Potentially Neoplastic

CE marking-compliant software; soon available in Europe

News provided by

NEC Corporation Tokyo Stock Exchange 6701

Jul. 15, 2021 10:20

A

Size

A A A A

TOKYO--(Business Wire / Korea Newswire)--NEC Corporation (NEC; TOKYO: 6701) announced today the development of an AI technology for supporting doctors in determining if colorectal lesions are neoplastic or non-neoplastic. NEC developed a new technology, called “Cx20,” while seeking to assist in the early detection of colorectal lesions. Cx20 has already met the requirements for CE marking, a European safety, health and environmental protection standard, and will be integrated in the medical device AI diagnostic support software “WISE VISION® Endoscopy” (*1), with sales expected to start in Europe later this year.

This software connects and interacts with existing endoscopic equipment and automatically notifies users if a lesion is possibly neoplastic based on images captured during endoscopy procedures. The software then becomes an extra tool immediately available to assist endoscopists in the differentiation of lesions and reduces the burden on patients.

Colorectal cancer originates from precancerous lesions (colorectal neoplastic polyps) and it is possible to suppress its progression by detecting and removing lesions at an early stage during endoscopy procedures. It is, however, sometimes difficult for endoscopists to visually distinguish between neoplastic and non-neoplastic lesions during endoscopy examinations, resulting in unnecessary biopsies and removal of non-neoplastic lesions, thereby causing additional stress and discomfort to patients. Colorectal cancer is said to be the second-largest cancer (*2) in the European region, and the latest version of WISE VISION® Endoscopy, which launches first in Europe, promises to help doctors address this challenging issue.

To improve the chances of identifying if colorectal lesions are possibly neoplastic, and so to help endoscopists in their decision process, NEC developed a new technology where the learning power of AI is used to combine information of endoscopy images and data from the findings of expert physicians. Specifically, the technology analyzes still images of lesions taken with endoscopy devices, and if the AI determines that a colorectal lesion is likely to be neoplastic a “High possibility” notification message is displayed.

For More Information
URL: https://www.nec.com/en/press/202107/global_20210714_03.html

Notes:
(*1) “WISE VISION” is a registered trademark of NEC Corporation in the United States of America, the European Union and the United Kingdom.

(*2) According to United European Gastroenterology
https://ueg.eu/p/78#

View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005377/en/

Website: http://www.nec.com

View Korean version of this release

Contact

NEC Corporation
Joseph Jasper

This news is a press release provided by NEC Corporation. Korea Newswire follows these editorial guidelines.

NEC Corporation News Releases

KEMRI and NEC Announce Trials on Biometric-based Vaccination Management System for Newborn Children in Kenya

The Kenya Medical Research Institute (KEMRI), NEC Corporation (NEC; TOKYO: 6701) and Nagasaki University have developed a digital biometric-based vaccination management system for newborn children in Kenya. Validation of this system is taking place through KEMRI with a clinical trial th...

2023년 2월 8일 10:30

KEMRI와 NEC, 케냐의 신생아를 대상으로 한 생체인식 기반 예방접종 관리 시스템 시험 발표

케냐의학연구소(The Kenya Medical Research Institute, KEMRI), NEC Corporation(NEC; TOKYO: 6701) 및 나가사키 대학교는 케냐의 신생아를 대상으로 하는 디지털 생체인식 기반 예방접종 관리 시스템을 개발했다. 이 시스템에 대한 검증은 KEMRI가 꽐레 소재 키낭고 지역정부병원에서 2022년 9월에 시작한 ...

2023년 2월 8일 10:30

... More

More News

All News Releases